Peripheral T-cell lymphoma
Xenothera’s clinical research includes relapsed/refractory peripheral T-cell lymphoma, with interest in treatments directed at malignant T-cell populations and disease control in aggressive hematologic cancer.
- Relapsed/refractory PTCL
- Anti-tumor activity in T-cell malignancy
- Safety and tolerability in hematologic oncology
The sponsor’s work in this area is centered on lymphoma therapy and the clinical assessment of novel antibody-based approaches for T-cell cancers.
Advanced and metastatic solid tumors
The sponsor also studies advanced or metastatic solid tumors, reflecting an oncology focus on cancers with limited treatment options and substantial unmet medical need.
- Advanced solid tumor malignancies
- Metastatic cancer
- Anti-tumor efficacy in refractory disease
Research in this category is aimed at evaluating novel immunotherapy concepts for difficult-to-treat solid cancers across multiple tumor types.
Antibody-based oncology
Xenothera’s pipeline features glyco-humanized polyclonal antibodies, placing therapeutic antibodies at the center of its oncology research activity.
- Polyclonal antibody therapeutics
- Targeted immune engagement
- Oncology biologics
This area links the sponsor’s interest in engineered biologics with treatment strategies for both hematologic and solid tumors.
Early clinical oncology development
The sponsor is active in first-in-human oncology research, with clinical programs that examine initial human safety, pharmacokinetics, and preliminary anti-tumor activity.
- First-in-human oncology studies
- Clinical safety evaluation
- Pharmacokinetic assessment
Its research activity spans multiple sites and countries, supporting clinical investigation in Europe and other active trial settings.
